Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoporosis - Pipeline Review, H1 2020, provides an overview of the Osteoporosis (Metabolic Disorders) pipeline landscape.
Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoporosis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 1, 8, 7, 22, 4, 63, 14 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 13 and 13 molecules, respectively.
Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoporosis (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteoporosis (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteoporosis (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
Introduction
Osteoporosis - Overview
Osteoporosis - Therapeutics Development
Osteoporosis - Therapeutics Assessment
Osteoporosis - Companies Involved in Therapeutics Development
Osteoporosis - Drug Profiles
Osteoporosis - Dormant Projects
Osteoporosis - Discontinued Products
Osteoporosis - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Osteoporosis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Products under Development by Companies, H1 2020 (Contd..7), H1 2020
Products under Development by Universities/Institutes, H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Osteoporosis - Pipeline by Ablynx NV, H1 2020
Osteoporosis - Pipeline by Abreos Biosciences Inc, H1 2020
Osteoporosis - Pipeline by Addpharma Inc, H1 2020
Osteoporosis - Pipeline by Aerami Therapeutics, H1 2020
Osteoporosis - Pipeline by Affilogic SAS, H1 2020
Osteoporosis - Pipeline by AgeX Therapeutics Inc, H1 2020
Osteoporosis - Pipeline by AlphaMab Co Ltd, H1 2020
Osteoporosis - Pipeline by Altum Pharmaceuticals Inc, H1 2020
Osteoporosis - Pipeline by Amgen Inc, H1 2020
Osteoporosis - Pipeline by Aryogen Pharmed Co, H1 2020
Osteoporosis - Pipeline by Axsome Therapeutics Inc, H1 2020
Osteoporosis - Pipeline by Bainan Biotech ApS, H1 2020
Osteoporosis - Pipeline by BIOCND Inc, H1 2020
Osteoporosis - Pipeline by Biosion Inc, H1 2020
Osteoporosis - Pipeline by Bone Biologics Corp, H1 2020
Osteoporosis - Pipeline by Bristol-Myers Squibb Co, H1 2020
Osteoporosis - Pipeline by Cadila Healthcare Ltd, H1 2020
Osteoporosis - Pipeline by Cellatoz Therapeutics Inc, H1 2020
Osteoporosis - Pipeline by ChoDang Pharm Co Ltd, H1 2020
Osteoporosis - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2020
Osteoporosis - Pipeline by Citragen Pharmaceuticals Inc, H1 2020
Osteoporosis - Pipeline by Corium, Inc., H1 2020
Osteoporosis - Pipeline by CSPC Pharmaceutical Group Ltd, H1 2020
Osteoporosis - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2020
Osteoporosis - Pipeline by Dong Wha Pharma Co Ltd, H1 2020
Osteoporosis - Pipeline by Dongkook Pharmaceutical Co Ltd, H1 2020
Osteoporosis - Pipeline by Eli Lilly and Co, H1 2020
Osteoporosis - Pipeline by EndoCeutics Inc, H1 2020
Osteoporosis - Pipeline by Enesi Pharma Ltd, H1 2020
Osteoporosis - Pipeline by Entera Bio Ltd, H1 2020
Osteoporosis - Pipeline by Enteris BioPharma Inc, H1 2020
Osteoporosis - Pipeline by Enzene Biosciences Ltd, H1 2020
Osteoporosis - Pipeline by Enzo Biochem Inc, H1 2020
Osteoporosis - Pipeline by Epygen Biotech Pvt Ltd, H1 2020
Osteoporosis - Pipeline by Evgen Pharma Plc, H1 2020
Osteoporosis - Pipeline by Galapagos NV, H1 2020
Osteoporosis - Pipeline by Genor BioPharma Co Ltd, H1 2020
Osteoporosis - Pipeline by GlycoNex Inc, H1 2020
Osteoporosis - Pipeline by GPN Therapeutics Inc, H1 2020
Osteoporosis - Pipeline by Haoma Medica Ltd, H1 2020
Osteoporosis - Pipeline by Helixmith Co Ltd, H1 2020
Osteoporosis - Pipeline by Hengenix Biotech Inc, H1 2020
Osteoporosis - Pipeline by Histide AG, H1 2020
Osteoporosis - Pipeline by HNB Therapeutics LLC, H1 2020
Osteoporosis - Pipeline by Hualan Biological Engineering Inc, H1 2020
Osteoporosis - Pipeline by Huons Co Ltd, H1 2020
Osteoporosis - Pipeline by Huons Global Co Ltd, H1 2020
Osteoporosis - Pipeline by IMGENEX India Pvt Ltd, H1 2020
Osteoporosis - Pipeline by Immunwork Inc, H1 2020
Osteoporosis - Pipeline by InnoPharmaScreen Inc, H1 2020
Osteoporosis - Pipeline by Innovent Biologics Inc, H1 2020
Osteoporosis - Pipeline by InSight Biopharmaceuticals Ltd, H1 2020
Osteoporosis - Pipeline by Intas Pharmaceuticals Ltd, H1 2020
Osteoporosis - Pipeline by Ipsen SA, H1 2020
Osteoporosis - Pipeline by JHL Biotech Inc, H1 2020
Osteoporosis - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020
Osteoporosis - Pipeline by Jiangsu T-mab BioPharma Co Ltd, H1 2020
Osteoporosis - Pipeline by Keros Therapeutics Inc, H1 2020
Osteoporosis - Pipeline by Kolmar Pharma Co Ltd, H1 2020
Osteoporosis - Pipeline by Kyoto Pharmaceutical Industries Ltd, H1 2020
Osteoporosis - Pipeline by LBL Biotech Corp, H1 2020
Osteoporosis - Pipeline by Lead Discovery Center GmbH, H1 2020
Osteoporosis - Pipeline by Lupin Ltd, H1 2020
Osteoporosis - Pipeline by Luye Pharma Group Ltd, H1 2020
Osteoporosis - Pipeline by Max Biopharma Inc, H1 2020
Osteoporosis - Pipeline by Merck & Co Inc, H1 2020
Osteoporosis - Pipeline by Mesentech Inc, H1 2020
Osteoporosis - Pipeline by Metabolab Inc, H1 2020
Osteoporosis - Pipeline by Millendo Therapeutics Inc, H1 2020
Osteoporosis - Pipeline by Nano Intelligent Biomedical Engineering Corp, H1 2020
Osteoporosis - Pipeline by Nanomedic Inc, H1 2020
Osteoporosis - Pipeline by NeuClone Pty Ltd, H1 2020
Osteoporosis - Pipeline by NovMetaPharma Co Ltd, H1 2020
Osteoporosis - Pipeline by Omeros Corp, H1 2020
Osteoporosis - Pipeline by Ortho Regenics Pvt Ltd, H1 2020
Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2020
Osteoporosis - Pipeline by Pfenex Inc, H1 2020
Osteoporosis - Pipeline by PhytoHealth Corp, H1 2020
Osteoporosis - Pipeline by Qilu Pharmaceutical Co Ltd, H1 2020
Osteoporosis - Pipeline by R Pharm, H1 2020
Osteoporosis - Pipeline by Regenerative Arthritis & Bone Medicine Inc, H1 2020
Osteoporosis - Pipeline by Reliance Life Sciences Pvt Ltd, H1 2020
Osteoporosis - Pipeline by Ribomic Inc, H1 2020
Osteoporosis - Pipeline by Sandoz International GmbH, H1 2020
Osteoporosis - Pipeline by Shandong Danhong Pharmaceutical Co Ltd, H1 2020
Osteoporosis - Pipeline by Shanghai Biomabs Pharmaceuticals Co Ltd, H1 2020
Osteoporosis - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2020
Osteoporosis - Pipeline by Shanghai Junshi Bioscience Co Ltd, H1 2020
Osteoporosis - Pipeline by Shenzhen Salubris Pharmaceuticals Co Ltd, H1 2020
Osteoporosis - Pipeline by Shin Poong Pharm Co Ltd, H1 2020
Osteoporosis - Pipeline by Stelis Biopharma Pvt Ltd, H1 2020
Osteoporosis - Pipeline by Suzhou Stainwei Biotech Inc, H1 2020
Osteoporosis - Pipeline by Taithera Inc, H1 2020
Osteoporosis - Pipeline by Terpenoid Therapeutics Inc, H1 2020
Osteoporosis - Pipeline by The National Institute for Biotechnology in the Negev Ltd, H1 2020
Osteoporosis - Pipeline by Tritech Biopharmaceuticals Co Ltd, H1 2020
Osteoporosis - Pipeline by TSH Biopharm Corporation Ltd, H1 2020
Osteoporosis - Pipeline by Uni-Bio Science Group Ltd, H1 2020
Osteoporosis - Pipeline by USV Pvt Ltd, H1 2020
Osteoporosis - Pipeline by Vibe Pharmaceuticals LLC, H1 2020
Osteoporosis - Pipeline by Vidasym Inc, H1 2020
Osteoporosis - Pipeline by Viking Therapeutics Inc, H1 2020
Osteoporosis - Pipeline by Yooyoung Pharm Co Ltd, H1 2020
Osteoporosis - Pipeline by Zosano Pharma Corp, H1 2020
Osteoporosis - Dormant Projects, H1 2020
Osteoporosis - Dormant Projects, H1 2020 (Contd..1), H1 2020
Osteoporosis - Dormant Projects, H1 2020 (Contd..2), H1 2020
Osteoporosis - Dormant Projects, H1 2020 (Contd..3), H1 2020
Osteoporosis - Dormant Projects, H1 2020 (Contd..4), H1 2020
Osteoporosis - Dormant Projects, H1 2020 (Contd..5), H1 2020
Osteoporosis - Dormant Projects, H1 2020 (Contd..6), H1 2020
Osteoporosis - Dormant Projects, H1 2020 (Contd..7), H1 2020
Osteoporosis - Dormant Projects, H1 2020 (Contd..8), H1 2020
Osteoporosis - Discontinued Products, H1 2020
Osteoporosis - Discontinued Products, H1 2020 (Contd..1), H1 2020
List of Figures
Number of Products under Development for Osteoporosis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
